ChiCTR2200056624 版本V1.3 版本创建时间2024/11/17 18:48:44 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200056624 

最近更新日期:

Date of Last Refreshed on:

2023-09-03 21:35:07 

注册时间:

Date of Registration:

2022-02-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

麻醉深度对结直肠癌患者术后淋巴细胞亚群及恢复质量的影响

Public title:

Effect of depth of Anesthesia on lymphocyte subsets and recovery quality of postoperative patients with Colorectal Cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

麻醉深度对结直肠癌患者术后淋巴细胞亚群及恢复质量的影响

Scientific title:

Effect of depth of Anesthesia on lymphocyte subsets and recovery quality of postoperative patients with Colorectal Cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

赵志斌 

研究负责人:

赵志斌 

Applicant:

Zhao Zhibin 

Study leader:

Zhao Zhibin 

申请注册联系人电话:

Applicant telephone:

+86 18961326661

研究负责人电话:

Study leader's
telephone:

+86 18961326661

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lygzhaozhibin@163.com

研究负责人电子邮件:

Study leader's E-mail:

lygzhaozhibin@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省连云港市海州区振华东路6号

研究负责人通讯地址:

江苏省连云港市海州区振华东路6号

Applicant address:

6, Zhenhua East Road, Haizhou District, Lianyungang, Jiangsu

Study leader's address:

6, Zhenhua East Road, Haizhou District, Lianyungang, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

222000

研究负责人邮政编码:

Study leader's postcode:

222000

申请人所在单位:

连云港市第一人民医院

Applicant's institution:

The First People's Hospital of Lianyungang

研究负责人所在单位:

连云港市第一人民医院

Affiliation of the Leader:

The First People's Hospital of Lianyungang

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-20211130002-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

连云港市第一人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Lianyungang First People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-01-29 00:00:00

伦理委员会联系人:

胡蓉

Contact Name of the ethic committee:

Hu Rong

伦理委员会联系地址:

江苏省连云港市海州区振华东路6号

Contact Address of the ethic committee:

6, Zhenhua East Road, Haizhou District, Lianyungang, Jiangsu

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

连云港市第一人民医院

Primary sponsor:

The First People's Hospital of Lianyungang

研究实施负责(组长)单位地址:

江苏省连云港市海州区振华东路6号

Primary sponsor's address:

6, Zhenhua East Road, Haizhou District, Lianyungang, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

连云港

Country:

China

Province:

Jiangsu

City:

Lianyungang

单位(医院):

连云港市第一人民医院

具体地址:

江苏省连云港市海州区振华东路6号

Institution
hospital:

The First People's Hospital of Lianyungang

Address:

6, Zhenhua East Road, Haizhou District, Lianyungang, Jiangsu

经费或物资来源:

连云港市第一人民医院

Source(s) of funding:

The First People's Hospital of Lianyungang

研究疾病:

结直肠癌手术麻醉  

Target disease:

Anesthesia for colorectal cancer surgery

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本试验拟通过在BIS监测下调控麻醉深度,观察其对结直肠癌患者术后淋巴细胞亚群的影响。  

Objectives of Study:

本试验拟通过在BIS监测下调控麻醉深度观察其对结直肠癌患者术后淋巴细胞亚群的影响

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 18≤年龄≤75岁,性别不限;
2.美国麻醉医师协会(ASA)评分为I级~III级;
3.体重指数(BMI):18 ~30 kg/m2;
4.无其他恶性肿瘤病史,术前两周内无输血史;
5.术前未进行放化疗,未使用免疫抑制剂者;
6.行择期腹腔镜下结直肠癌手术,预计手术时间不低于1小时;
7.小学及以上文凭,可以完成量表测量者;
8.清楚了解、自愿参加该项研究,并签署知情同意书。

Inclusion criteria

1. 18 ≤ age ≤ 75 years old, gender unlimited;
2. The score of American Association of Anesthesiologists (ASA) is from grade I to grade III;
3. Body mass index (BMI): 18~30 kg/m2;
4. No history of other malignant tumors and no blood transfusion history within two weeks before operation;
5. Those who did not undergo radiotherapy and chemotherapy before operation and did not use immunosuppressants;
6. Perform elective laparoscopic surgery for colorectal cancer, and the estimated operation time is not less than 1 hour;
7. Primary school diploma or above, who can complete the scale measurement;
8. Clearly understand and voluntarily participate in the study, and sign the informed consent form.

排除标准:

1.急诊手术、低血容量、 休克或者昏迷状态;
2.合并严重的心脑血管、肝、肾、精神类疾病史;
3.术前两周内有免疫抑制剂及抗炎药物使用史
4.术前存在放化疗史,肿瘤已有远处转移者;
5.不能完成量表测量者;
6.研究者认为不宜参加此试验的其他情况。

Exclusion criteria:

1. Emergency surgery, hypovolemia, shock or coma;
2. History of severe cardiovascular, cerebrovascular, liver, kidney and psychiatric diseases;
3. Have a history of using immunosuppressive and anti-inflammatory drugs within two weeks before operation
4. Patients who have a history of radiotherapy and chemotherapy before operation and have distant metastasis of tumor;
5. Those who cannot complete the scale measurement;
6. Other circumstances in which the researcher considers it inappropriate to participate in this test.

研究实施时间:

Study execute time:

From 2022-02-01 00:00:00 To 2023-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-02-06 00:00:00 To 2023-12-01 00:00:00

干预措施:

Interventions:

组别:

L组

样本量:

30

Group:

L group

Sample size:

干预措施:

控制BIS在较低水平

干预措施代码:

Intervention:

Control BIS at a lower level

Intervention code:

组别:

D组

样本量:

30

Group:

D group

Sample size:

干预措施:

控制BIS在较高水平

干预措施代码:

Intervention:

Control BIS at a high level

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

连云港 

Country:

China

Province:

Jiangsu

City:

Lianyungang

单位(医院):

连云港市第一人民医院 

单位级别:

三甲 

Institution
hospital:

The First People's Hospital of Lianyungang

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

淋巴细胞亚群数量

指标类型:

主要指标

Outcome:

Number of lymphocyte subsets

Type:

Primary indicator

测量时间点:

术后

测量方法:

流式细胞仪

Measure time point of outcome:

postoperative

Measure method:

Flow cytometer

指标中文名:

术后恢复质量

指标类型:

次要指标

Outcome:

Postoperative recovery quality

Type:

Secondary indicator

测量时间点:

postoperative

测量方法:

量表测量

Measure time point of outcome:

术后

Measure method:

Scale measurement

指标中文名:

脑氧饱和度

指标类型:

次要指标

Outcome:

Cerebral oxygen saturation

Type:

Secondary indicator

测量时间点:

术中

测量方法:

脑氧监测仪

Measure time point of outcome:

intraoperative

Measure method:

Brain oxygen monitor

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表法

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

医院内部公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Open inside the hospital

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-02-09 04:50:25